Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial

Au, Heather-Jane, Karapetis, Christos S., O'Callaghan, Chris J., Tu, Dongsheng, Moore, Malcolm J., Zalcberg, John R., Kennecke, Hagen, Shapiro, Jeremy D., Koski, Sheryl, Pavlakis, Nick, Charpentier, Danielle, Wyld, David, Jefford, Michael, Knight, Gregory J., Magoski, Nadine M., Brundage, Michael D. and Jonker, Derek J. (2009) Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27 11: 1822-1828. doi:10.1200/JCO.2008.19.6048

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ367939_OA.pdf application/pdf 266.04KB 0

Author Au, Heather-Jane
Karapetis, Christos S.
O'Callaghan, Chris J.
Tu, Dongsheng
Moore, Malcolm J.
Zalcberg, John R.
Kennecke, Hagen
Shapiro, Jeremy D.
Koski, Sheryl
Pavlakis, Nick
Charpentier, Danielle
Wyld, David
Jefford, Michael
Knight, Gregory J.
Magoski, Nadine M.
Brundage, Michael D.
Jonker, Derek J.
Title Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial
Journal name Journal of Clinical Oncology   Check publisher's open access policy
ISSN 0732-183X
1527-7755
Publication date 2009-04-10
Sub-type Article (original research)
DOI 10.1200/JCO.2008.19.6048
Open Access Status File (Publisher version)
Volume 27
Issue 11
Start page 1822
End page 1828
Total pages 7
Place of publication Alexandria, VA United States
Publisher American Society of Clinical Oncology
Language eng
Abstract Purpose National Cancer Institute of Canada Clinical Trials Group CO.17 demonstrated the antiepidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab improves overall and progression-free survival in patients with advanced, chemotherapy-refractory colorectal cancer (CRC), particularly in patients with wild-type KRAS tumors. This article reports the health-related quality-of-life (HRQL) outcomes from CO.17. Patients and Methods Patients (N = 572) with pretreated EGFR-detectable advanced CRC were randomly assigned to cetuximab and best supportive care (BSC) or to BSC alone. HRQL primary end points assessed by the EORTC QLQ-C30 were physical function (PF) and global health status (GHS); mean changes from baseline to 8 and 16 weeks were assessed. Post hoc analysis by KRAS mutation status was performed. Results Questionnaire compliance was 94% at baseline, but it declined differentially (67% v 47% for cetuximab v BSC at 16 weeks). PF change scores were -3.9 for cetuximab and -8.6 for BSC (P =.046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P =.027) at 16 weeks. GHS change scores were -0.5 and -7.1 (P =.008) at 8 weeks and were -3.6 and -15.2 (P =.008) at 16 weeks for cetuximab and BSC, respectively. In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v-7.2; P =.11) and 16 weeks (-3.4 v -13.8; P =.008) compared with BSC. Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P =.002). Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P <.001). No significant differences were noted between study arms for patients with mutated KRAS tumors. Conclusion Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 55 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 60 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 26 Aug 2015, 19:23:40 EST by Anthony Yeates on behalf of Medicine - Royal Brisbane and Women's Hospital